Singapore and Princeton, NJ – May 19, 2025 – Shanton Pharma, a clinical-stage biotech company developing a novel treatment for gout, today announced that it will be presenting topline data of its phase 2b study in refractory gout patients at the annual EULAR Congress in Barcelona on June 14.
Singapore and Princeton, NJ – March 27, 2025 – Shanton Pharma, a clinical-stage biotech company developing a novel treatment for gout, today announced topline data of a Phase 2b study in refractory gout patients with its investigational drug SAP-001 that uses a First-in-Class Mechanism of Action targeting a distinct kidney transporter.
SAP-001 is Shanton’s lead investigational compound with Best-in-Class potential in uncontrolled gout
The Shanton Pharma Phase 2 study evaluating its investigational product SAP-001, an oral, small molecule, achieved its primary endpoint. In the trial, SAP-001 significantly reduce uric acid . SAP-001 was well tolerated.
– Established China Biotechnology Company with Global Headquarters in the United States – Proceeds will advance clinical development of SAP-001 clinical trials for hyperuricemia and gout Based in Shanghai, Shanton Pharma is a private clinical-stage biotechnology company dedicated to the research, development and commercialization of innovative medicines in areas of unmet medical need, closed a $31.2 million Series A+ financing in December of 2020. The proceeds will be used to accelerate the p